A phase IV, non-randomised, study of Modrenal (Trilostane) in post-menopausal women with advanced, oestrogen receptor positive breast cancer for whom prior endocrine therapies have failed, one of which was an aromatase inhibitor
Latest Information Update: 05 Sep 2019
Price :
$35 *
At a glance
- Drugs Trilostane (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bioenvision
- 05 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 May 2006 New trial record.